RecruitingInterventionalPhase 3Last updated Jul 31, 2026

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Overview

ClinicalTrials.gov ID: NCT07252232
Lead Sponsor: Revolution Medicines, Inc.INDUSTRY
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Dec 15, 2025Actual
Primary Completion Date: May 10, 2029Estimated
Completion Date: Jul 10, 2030Estimated

Study Record Dates

First Submitted: Nov 13, 2025
First Submitted that Met QC Criteria: Nov 18, 2025
First Posted: Nov 26, 2025Actual
Last Update Submitted that Met QC Criteria: Jul 30, 2026
Last Update Posted: Jul 31, 2026Actual
Last Verified: Jun 2026

NCT06625320Active, not recruiting

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07491445Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT06881784Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT07621718Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT07573215Available

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma